An ongoing phase I study of patients who have experienced relapsed and/or refractory multiple myeloma has found that this population was largely able to tolerate a new oral 20S proteasome inhibitor after receiving other prior treatments.
An ongoing phase I study of patients who have experienced relapsed and/or refractory multiple myeloma has found that this population was largely able to tolerate a new oral 20S proteasome inhibitor after receiving other prior treatments.
An abstract on MLN9708 was presented this week at the 2013 Annual Meeting of the American Society of Clinical Oncology in Chicago that reported the safety, activity, and pharmacokinetics of the agent in a phase I trial.
Researchers led by Shaji Kumar, MD, at the Mayo Clinic in Rochester, Minnesota, are investigating MLN9708, a medication that had decreased tumor activity in in vivo models of multiple myeloma. MLN0708 was administered weekly to a group of 60 patients, including 33 males. Study participants ranged from 40 to79 years, with a median age of 64. Patients received MLN9708 at a dose of 0.24-3.95 mg/m2 (dose-escalation phase, 32 patients), and at the maximum-tolerated dose of 2.97 mg/m2 in relapsed/refectory, bortezomib-relapsed, proteasome inhibitor-relapsed patients, and patients who received prior carfilzomib therapy (expansion cohort, 31 patients).
Median time from multiple myeloma diagnosis was 4.9 years, with a range of 1.5 to 18.8 years. Median number of prior regimens was six, with a range of two to 18; 76% of patients were refractory to their last therapy.
At the last data cut-off on November 29, 2012, the patients had received a median of two cycles (1 to 11 cycles), and five patients remained on treatment.
Adverse effects (AEs) of grade 3 or less were seen in 83% of patients. In 52% of patients, there were common drug-related AEs of grade 3 or less, including thrombocytopenia (33%), diarrhea, neutropenia (17%), decreased appetite, fatigue, and lymphopenia (8%). Six patients had drug-related parenteral nutrition. Five patients stopped therapy due to AEs, and one patient died on study due to an unrelated AE.
Weekly oral MLN9708 was generally well-tolerated and showed activity in this heavily pretreated population who had prior exposure to immunomodulatory drugs and bortezomib.
________________________________________
Kumar S, Bensinger W, Zimmerman TM, et al. Weekly MLN9708, an investigational oral proteasome inhibitor, in relapsed/refractory multiple myeloma: results from a phase I study after full enrollment. J Clin Oncol. 2013;(suppl; abstr 8514).
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More